Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
P.M. Clarke, A.M. Gray, A. Briggs, R.J. Stevens, D.R. Matthews, R.R. Holman, and on behalf of the UK Prospective Diabetes Study (UKPDS)
Diabetologia (2005) 48: 868-877
Aims/hypothesis This study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight.
Methods We conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model.
Results The incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was £6,028, and for blood pressure control was £369. Metformin therapy was cost-saving and increased quality-adjusted life expectancy.
Conclusions/interpretation Each of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions.